Presage Biosciences Presents Proof-of-Concept Data for CIVO™ Preclinical Assessment Platform at AACR 2014
April 8, 2014 | SEATTLE, Wash.
Presage Biosciences Named a “Fierce 15” Biotech Company of 2013 by FierceBiotech
Sept. 24, 2013 | SEATTLE, Wash.
Treating Kids' Cancer With Science And A Pocket Full Of Hope
Sept. 13, 2013 | NPR Morning Edition
Founder Jim Olson Speaks at TedX Seattle
June 23, 2013 | SEATTLE, Wash.
Presage Biosciences is dedicated to improving the cancer drug development
process so that patients can receive the most effective treatment possible.
Our proprietary technology platform allows for the rapid, reliable assessment of multiple cancer therapeutics in an in vivo setting, providing the first side-by-side comparison of multiple drugs and drug combinations within a single living tumor.